Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies
Spondyloarthropathy (SpA) is a unique type of joint inflammation characterized by coexisting erosive bone damage and pathological new bone formation. Previous genetic association studies have demonstrated that several cytokine pathways play a critical role in the pathogenesis of ankylosing spondylit...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2018/2403935 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546028089245696 |
|---|---|
| author | I-Tsu Chyuan Ji-Yih Chen |
| author_facet | I-Tsu Chyuan Ji-Yih Chen |
| author_sort | I-Tsu Chyuan |
| collection | DOAJ |
| description | Spondyloarthropathy (SpA) is a unique type of joint inflammation characterized by coexisting erosive bone damage and pathological new bone formation. Previous genetic association studies have demonstrated that several cytokine pathways play a critical role in the pathogenesis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and other types of SpA. In addition to several well-known proinflammatory cytokines, recent studies suggest that IL-17 plays a pivotal role in the pathogenesis of SpA. Further evidence from human and animal studies have defined that IL-17 and IL-17-producing cells contribute to tissue inflammation, autoimmunity, and host defense, leading to the following pathologic events associated with SpA. Recently, several clinical trials targeting IL-17 pathways demonstrated the positive response of IL-17 blockade in treating AS, indicating a great potential of IL-17-targeting therapy in SpA. In this review article, we have discussed the contributing role of IL-17 and different IL-17-producing cells in the pathogenesis of SpA and provided an outline of therapeutic application of the IL-17 blockade in the treatment of SpA. Other targeted cytokines associated with IL-17 axis in SpA will also be included. |
| format | Article |
| id | doaj-art-e7dbac634e904efbb7f608597f843406 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-e7dbac634e904efbb7f608597f8434062025-02-03T07:24:03ZengWileyMediators of Inflammation0962-93511466-18612018-01-01201810.1155/2018/24039352403935Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in SpondyloarthropathiesI-Tsu Chyuan0Ji-Yih Chen1Department of Internal Medicine, Cathay General Hospital, Taipei, TaiwanDepartment of Medicine, Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Taoyuan, TaiwanSpondyloarthropathy (SpA) is a unique type of joint inflammation characterized by coexisting erosive bone damage and pathological new bone formation. Previous genetic association studies have demonstrated that several cytokine pathways play a critical role in the pathogenesis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and other types of SpA. In addition to several well-known proinflammatory cytokines, recent studies suggest that IL-17 plays a pivotal role in the pathogenesis of SpA. Further evidence from human and animal studies have defined that IL-17 and IL-17-producing cells contribute to tissue inflammation, autoimmunity, and host defense, leading to the following pathologic events associated with SpA. Recently, several clinical trials targeting IL-17 pathways demonstrated the positive response of IL-17 blockade in treating AS, indicating a great potential of IL-17-targeting therapy in SpA. In this review article, we have discussed the contributing role of IL-17 and different IL-17-producing cells in the pathogenesis of SpA and provided an outline of therapeutic application of the IL-17 blockade in the treatment of SpA. Other targeted cytokines associated with IL-17 axis in SpA will also be included.http://dx.doi.org/10.1155/2018/2403935 |
| spellingShingle | I-Tsu Chyuan Ji-Yih Chen Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies Mediators of Inflammation |
| title | Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies |
| title_full | Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies |
| title_fullStr | Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies |
| title_full_unstemmed | Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies |
| title_short | Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies |
| title_sort | role of interleukin il 17 in the pathogenesis and targeted therapies in spondyloarthropathies |
| url | http://dx.doi.org/10.1155/2018/2403935 |
| work_keys_str_mv | AT itsuchyuan roleofinterleukinil17inthepathogenesisandtargetedtherapiesinspondyloarthropathies AT jiyihchen roleofinterleukinil17inthepathogenesisandtargetedtherapiesinspondyloarthropathies |